Cytek Biosciences, Inc. (CTKB) P/E Ratio History
Historical price-to-earnings valuation from 2021 to 2022
Loading P/E history...
CTKB Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 9, 2026, Cytek Biosciences, Inc. (CTKB) trades at a price-to-earnings ratio of -8.9x, with a stock price of $4.61 and trailing twelve-month earnings per share of $-0.57.
The current P/E is 102% below its 5-year average of 456.3x. Over the past five years, CTKB's P/E has ranged from a low of 265.3x to a high of 590.2x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 21.9x, CTKB trades at a 140% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 176.0x.
Relative to the broader market, CTKB trades at a notable discount to the S&P 500 median P/E of 24.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CTKB DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CTKB P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $22B | 26.0 | 6.15 | +171%Best | |
| $17B | 30.5 | - | -25% | |
| $7B | 9.1Lowest | - | +143% | |
| $23B | 33.0 | 6.38 | +0% | |
| $173B | 26.2 | 12.41 | +7% | |
| $33B | 25.3 | 1.72Best | +3% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
CTKB Historical P/E Data (2021–2022)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $10.21 | $0.02 | 590.2x | +29% |
| FY2022 Q1 | $10.78 | $0.02 | 531.0x | +16% | |
| FY2021 Q4 | Fri Dec 31 2021 00:00:00 GM | $16.32 | $0.04 | 438.7x | -4% |
| FY2021 Q3 | $21.41 | $0.08 | 265.3x | -42% |
Average P/E for displayed period: 456.3x
See CTKB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CTKB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CTKB vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCTKB — Frequently Asked Questions
Quick answers to the most common questions about buying CTKB stock.
Is CTKB stock overvalued or undervalued?
CTKB trades at -8.9x P/E, below its 5-year average of 456.3x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does CTKB's valuation compare to peers?
Cytek Biosciences, Inc. P/E of -8.9x compares to sector median of 21.9x. The discount suggests lower growth expectations or higher risk.
What is CTKB's PEG ratio?
CTKB PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2021-2022.